Rubicon CEO CopilotDemo Data
Rubicon · The growth engine

R&D Productivity & PipelineAbout this pageRubicon frames R&D as 'the DNA of the company' and tracks a productivity multiple — three-year incremental revenue divided by the trailing nine quarters of R&D spend. This page makes that flywheel visible: the multiple, the spend discipline, the pipeline funnel, and the specialty mix-shift that lifts margins.

Management's lead indicator: every ₹1 of R&D now returns 5.9× in incremental revenue — up from 3.3×. With a 93% commercialization rate and <5% non-productive spend, R&D is the compounding flywheel.

The engine in numbersThe engine in numbersThe efficiency metrics management points to as proof the R&D rupee is well spent — and the forward commitments that underwrite FY29–FY30 visibility.

R&D productivity
5.9×
FY26 · target >5×
Commercialization
93%
of approved products
Non-productive R&D
<5%
disciplined selection
FDA approvals FY26
12
24 under review
Forward R&D
>₹500 cr
FY26 + FY27 + Q1 FY28 (9 quarters)
R&D scientists
140
2 R&D centres

Productivity is rising, not just spendProductivity is rising, not just spendThe multiple climbed from 3.3× to 5.9× while R&D held at ~10–11% of revenue. The improvement comes from the colour of the book — a shift toward specialty, drug-device and branded products — not from spending more.

R&D productivity multipleHow this worksEach bar is a rolling vintage. 3.3× → ₹165 cr of R&D yielded ₹540 cr of incremental revenue; 5.9× → the FY26 vintage. Management guides to 'upward of 5×' going forward.

3Y incremental revenue ÷ trailing-9Q R&D

Spend discipline

R&D as % of revenue

FY24
13%
FY25
10.5%
FY26
11%

Held at 10–11% of revenue for the next 3–4 years, sustainable “over 5 years.” The forward commitment is > ₹500 cr across FY26 + FY27 + Q1 FY28 (9 quarters).

Productivity > 5× on that spend is what management says creates “very strong revenue growth visibility for FY29, FY30 and beyond.”

The pipeline funnelThe pipeline funnelRubicon's value loop in one view: ideas become filings, filings become approvals, approvals become commercial products, and a select 16 become specialty franchises that punch above their weight on gross profit. The 93% commercialization rate means almost nothing approved is wasted.

In active development
incl. UK, Canada, Australia, South Africa filings
63
Pending FDA approval
ANDAs awaiting action
17
FDA-approved (ANDA + NDA)
73 ANDAs + 9 NDAs
82
Commercialized in US
93% commercialization rate
76
Specialty (≤1 competitor)
32.5% of gross profit
16

73 ANDAs + 9 NDAs approved · 66 commercialized products · 5 approved intranasal sprays on the drug-device platform.

Why the mix mattersWhy the mix mattersSpecialty products — defined as facing no more than one competitor for a year after launch — have gone from 13% of gross profit (FY23) to 32.5% (FY26). That mix-shift is the structural reason margins and productivity are both improving.

Specialty share of gross profit

The mix-shift that lifts margin

13%
FY23
26.9%
FY25
32.5%
FY26

16 specialty products = 32.5% of gross profit. The list is dynamic — even when a product loses exclusivity, “the margin profile stays fairly healthy.”

Therapy focus

Revenue by therapy area

CNS
27%
Analgesics / Pain
24%
Cardiovascular
19%
Hypokalemia
7.5%
Metabolic
5%
Immunosuppressants
4.5%
Muscle Relaxants
3.5%

CNS + Analgesics + CVS together are 70% of revenue — and CNS is exactly where the drug-device “nose-to-brain” platform and the Arinna India go-to-market are aimed.

Source: Rubicon Q2–Q4 FY26 earnings calls and disclosures. Productivity multiples are management's stated framework (rolling 9-quarter R&D vs 3-year incremental revenue).